Skip to main content

Find Clinical Trials

Home
Conditions
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Clinical trial condition

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Explore clinical trials studying Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK). Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) trial results

Completed

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

NCT01634763

Conditions: Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Locations: Novartis Investigative Site Sunto-gun, Shizuoka, Japan

Novartis Investigative Site Koto, Tokyo, Japan

Novartis Investigative Site Fukuoka, Japan

View Trial Details